Current Issue February 2012, Vol. 48, No. 3
Issue Highlights
-
Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991January 2012 (Vol. 48 | No. 2 | Pages 218-225)
-
Targeted agents: How to select the winners in preclinical and early clinical studies?January 2012 (Vol. 48 | No. 2 | Pages 170-178)
-
The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trialsJanuary 2012 (Vol. 48 | No. 2 | Pages 187-195)
EJC News Focus
The largest ever screening trial in lung cancer reported last year that screening with low-dose CT reduces mortality from the disease. This impressive trial, from the US’ National Lung Screening Trial Research Team, demonstrated that CT scans could detect both early stage and advanced disease. So - does that mean that lung screening is set to become a reality in many countries? Not in the short term, says EJC’s Lung Cancer Editor, Mary O’Brien (Royal Marsden Hospital, Sutton, Surrey, UK). She told Helen Saul that other ongoing trials will take between 5 and 10 years to report, and that these results will be needed to answer outstanding questions before expensive screening programmes can be considered. But in the meantime, she applauds the trial and says it holds important messages for both clinicians and patients.
-
Stop and go strategy for opioid switching requires flexibility06 February 2012
-
Identification of Familial Adenomatous Polyposis carriers among children with desmoid tumours06 February 2012
-
Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer06 February 2012
-
Treatment strategies for patients with stage IV rectal cancer: A report from the Swedish Rectal Cancer Registry06 February 2012
-
Reply to Professor Mercadante: Stop and go strategy for opioid switching requires flexibility03 February 2012
